Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
about
From selection hits to clinical leads: progress in aptamer discoveryModulation of the Coagulation Cascade Using AptamersBiology of tissue factor pathway inhibitor.Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Differential Contributions of Intrinsic and Extrinsic Pathways to Thrombin Generation in Adult, Maternal and Cord Plasma Samples.Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation.Molecular approaches for improved clotting factors for hemophilia.Advances in the treatment of inherited coagulation disorders.Aptamers as targeted therapeutics: current potential and challenges.Identification and application of ssDNA aptamers against H₃₇Rv in the detection of Mycobacterium tuberculosis.Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.Immunological and hematological toxicities challenging clinical translation of nucleic acid-based therapeutics.Longer-acting clotting factor concentrates for hemophilia.Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia.Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorderAlprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.The use of frozen plasma samples in thromboelastometry.Suppressive Role of Tissue Factor Pathway Inhibitor-α in Platelet-Dependent Fibrin Formation under Flow Is Restricted to Low Procoagulant Strength.The Potential Close Future of Hemophilia Treatment - Gene Therapy, TFPI Inhibition, Antithrombin Silencing, and Mimicking Factor VIII with an Engineered Antibody.Prevention and Management of Bleeding Episodes in Children with Hemophilia
P2860
Q26752799-A8B223B4-7C42-41D6-AF95-0DD3ED5BF2F1Q28816936-185F10B0-208B-49B8-AE56-6AC1DFACD632Q33585249-0AFA56A1-750A-4AE7-A1E3-6186CA11258DQ34045763-772769E5-2959-48C9-B42D-933F792C7FB1Q36022423-ECD236AF-3A71-4F0F-8527-0FCE459DCFC5Q37276726-1B1F470E-EBC6-4469-8B76-D80E65D77716Q37334700-F7326611-0775-42C5-9BFC-E217CADCD8C5Q38100271-524274B1-65C3-4868-ADDC-31B1966F1DB7Q38290290-1DB95F4A-F797-4ED3-A7D2-D7437FC3A05FQ38297501-9F501686-C81C-45C9-8B9E-00DCDAA7ACF5Q38316749-79386675-F75E-450F-AE43-1B27B7F34F86Q38504825-D8CB4C8F-4EF1-4962-9622-D4ABBF4800EEQ38543283-C2EAF3FF-9462-4644-AFEE-4FB9BAFECF48Q42360054-B807C617-BD32-4A8A-AF16-A8332C490B32Q42572915-59EC0090-679D-4409-AB56-730825A74B1FQ44051815-A4A15F28-E83F-4168-8694-4004CE5D5ED6Q47156309-446CFAA6-EC50-4E4D-86FC-5CCCC40F1016Q49922306-F0315A74-DFE4-4245-A1F6-07A95DFF68EAQ55211396-84264086-4BB0-49A7-AAA5-B1F886C1A20DQ58726516-4B525E7C-3E3A-4A11-943A-F560811B03E8
P2860
Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Inhibition of tissue factor pa ...... f hemophilic blood and plasma.
@en
Inhibition of tissue factor pa ...... f hemophilic blood and plasma.
@nl
type
label
Inhibition of tissue factor pa ...... f hemophilic blood and plasma.
@en
Inhibition of tissue factor pa ...... f hemophilic blood and plasma.
@nl
prefLabel
Inhibition of tissue factor pa ...... f hemophilic blood and plasma.
@en
Inhibition of tissue factor pa ...... f hemophilic blood and plasma.
@nl
P2093
P2860
P1476
Inhibition of tissue factor pa ...... of hemophilic blood and plasma
@en
P2093
A Srivastava
I Pabinger
J C Gilbert
K E McGinness
M E Gorczyca
R G Schaub
P2860
P304
P356
10.1111/J.1538-7836.2012.04790.X
P577
2012-08-01T00:00:00Z